Abstract
We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 μg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis. Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment. The mean ±SD mineralization surfaces as a percent of bone surfaces (MS/BS, %) at the trabecular level were 7.73 + 1.48% for teriparatide and 5.25 ± 1.15% for SrR (p = 0.219) and at the endocortical level were 17.22 ± 3.06% and 9.70 ± 2.07%, respectively (p = 0.052). Cortical porosity was 5.40 ± 0.41% in the teriparatide and 4.14 ± 0.40% in the SrR group (p = 0.037). Teriparatide induced significant increases from baseline in bone formation and resorption markers, reaching statistical significance for amino-terminal propeptide of type I collagen (PINP) after 1 mo (+57%, p ± 0.001). SrR induced small, but statistically significant, reductions from baseline in PINP at 3 (-14%, p = 0.005) and 6 mo (-19%, p <0.001) and in serum ß-C-terminal telopeptide of type I collagen (ß-CTX) at 1 and 3 mo (-11%, for both, p <0.05). There were more patients with adverse events after SrR (70%) than teriparatide (41%) treatment (p = 0.013). In conclusion, the changes in biochemical markers of bone formation confirmed bone-forming activity of teriparatide but not of SrR treatment. The effects of SrR on bone remodeling and cell activity were modest, indicating that its effects on fracture reduction may be predominantly mediated through a different mechanism than that observed with anabolic or more potent antiresorptive agents.
| Original language | English |
|---|---|
| Pages (from-to) | 1358-1368 |
| Number of pages | 11 |
| Journal | Journal of Bone and Mineral Research |
| Volume | 24 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2009 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Orthopedics and Sports Medicine
- Endocrinology, Diabetes and Metabolism
Cite this
Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. / Recker, Robert R.; Marin, Fernando; Ish-Shalom, Sophia; Möricke, Rüdiger; Hawkins, Federico; Kapetanos, Georgios; De La Peña, Maria P.; Kekow, Jörn; Farrerons, Jordi; Sanz, Beatriz; Oertel, Heide; Stepan, Jan.
In: Journal of Bone and Mineral Research, Vol. 24, No. 8, 08.2009, p. 1358-1368.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis
AU - Recker, Robert R.
AU - Marin, Fernando
AU - Ish-Shalom, Sophia
AU - Möricke, Rüdiger
AU - Hawkins, Federico
AU - Kapetanos, Georgios
AU - De La Peña, Maria P.
AU - Kekow, Jörn
AU - Farrerons, Jordi
AU - Sanz, Beatriz
AU - Oertel, Heide
AU - Stepan, Jan
PY - 2009/8
Y1 - 2009/8
N2 - We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 μg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis. Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment. The mean ±SD mineralization surfaces as a percent of bone surfaces (MS/BS, %) at the trabecular level were 7.73 + 1.48% for teriparatide and 5.25 ± 1.15% for SrR (p = 0.219) and at the endocortical level were 17.22 ± 3.06% and 9.70 ± 2.07%, respectively (p = 0.052). Cortical porosity was 5.40 ± 0.41% in the teriparatide and 4.14 ± 0.40% in the SrR group (p = 0.037). Teriparatide induced significant increases from baseline in bone formation and resorption markers, reaching statistical significance for amino-terminal propeptide of type I collagen (PINP) after 1 mo (+57%, p ± 0.001). SrR induced small, but statistically significant, reductions from baseline in PINP at 3 (-14%, p = 0.005) and 6 mo (-19%, p <0.001) and in serum ß-C-terminal telopeptide of type I collagen (ß-CTX) at 1 and 3 mo (-11%, for both, p <0.05). There were more patients with adverse events after SrR (70%) than teriparatide (41%) treatment (p = 0.013). In conclusion, the changes in biochemical markers of bone formation confirmed bone-forming activity of teriparatide but not of SrR treatment. The effects of SrR on bone remodeling and cell activity were modest, indicating that its effects on fracture reduction may be predominantly mediated through a different mechanism than that observed with anabolic or more potent antiresorptive agents.
AB - We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 μg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis. Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment. The mean ±SD mineralization surfaces as a percent of bone surfaces (MS/BS, %) at the trabecular level were 7.73 + 1.48% for teriparatide and 5.25 ± 1.15% for SrR (p = 0.219) and at the endocortical level were 17.22 ± 3.06% and 9.70 ± 2.07%, respectively (p = 0.052). Cortical porosity was 5.40 ± 0.41% in the teriparatide and 4.14 ± 0.40% in the SrR group (p = 0.037). Teriparatide induced significant increases from baseline in bone formation and resorption markers, reaching statistical significance for amino-terminal propeptide of type I collagen (PINP) after 1 mo (+57%, p ± 0.001). SrR induced small, but statistically significant, reductions from baseline in PINP at 3 (-14%, p = 0.005) and 6 mo (-19%, p <0.001) and in serum ß-C-terminal telopeptide of type I collagen (ß-CTX) at 1 and 3 mo (-11%, for both, p <0.05). There were more patients with adverse events after SrR (70%) than teriparatide (41%) treatment (p = 0.013). In conclusion, the changes in biochemical markers of bone formation confirmed bone-forming activity of teriparatide but not of SrR treatment. The effects of SrR on bone remodeling and cell activity were modest, indicating that its effects on fracture reduction may be predominantly mediated through a different mechanism than that observed with anabolic or more potent antiresorptive agents.
UR - http://www.scopus.com/inward/record.url?scp=68949100644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68949100644&partnerID=8YFLogxK
U2 - 10.1359/jbmr.090315
DO - 10.1359/jbmr.090315
M3 - Article
C2 - 19338452
AN - SCOPUS:68949100644
VL - 24
SP - 1358
EP - 1368
JO - Journal of Bone and Mineral Research
JF - Journal of Bone and Mineral Research
SN - 0884-0431
IS - 8
ER -